Feature Channels: Clinical Trials

• share
• favorite_border

A new international study published in and presented as a late-breaking abstract at the American Association of Neurological Surgeons (AANS) annual conference, shows great promise for patients with glioblastoma. Drs. Farshad Nassiri and Gelareh Zadeh, neurosurgeons and scientists at the University Health Network (UHN) in Toronto, published the results of a Phase 1/2 clinical trial investigating the safety and effectiveness of a novel therapy which combines the injection of an oncolytic virus – a virus that targets and kills cancer cells – directly into the tumour, with intravenous immunotherapy.

• share
• favorite_border

We’re mere days away from the largest gathering of respiratory health professionals! You can still register to cover ATS 2023 in Washington, DC. Before you join us, here are some of the research abstracts that will be presented to this year’s gathering of pulmonary, critical care and sleep medicine health professionals.

• share
• favorite_border

Intratumoral delivery of an engineered oncolytic virus (DNX-2401) targeting glioblastoma (GBM) cells combined with subsequent immunotherapy was safe and improved survival outcomes in a subset of patients with recurrent GBM, according to results from a multi-institutional Phase I/II clinical trial co-led by researchers at The University of Texas MD Anderson Cancer Center and the University of Toronto.

• share
• favorite_border

Value in Health, the official journal of ISPOR, announced today the publication of an ISPOR Good Practices Report providing recommendations for assessing the need to demonstrate comparability among ways to collect patient responses.

• share
• favorite_border

For patients with kidney stones measuring one to two centimeters, a technique called mini-percutaneous nephrolithotomy (mini-PCNL) provides a higher stone elimination rate than another minimally invasive procedure called ureteroscopy (URS), concludes a randomized trial in the June issue of The Journal of Urology®, an Official Journal of the American Urological Association (AUA). The journal is published in the Lippincott portfolio by Wolters Kluwer.

• share
• favorite_border

A pneumonia trial – the largest ever led by the University of Bristol – will investigate whether aspirin can reduce the risk of a heart attack or stroke in patients who are admitted to hospital with pneumonia.

• share
• favorite_border

• share
• favorite_border

University of Maryland School of Medicine (UMSOM) Dean Mark T. Gladwin, MD, announced today that Bradley A. Maron, MD, Associate Professor of Medicine at Brigham & Women’s Hospital (BWH) and Harvard Medical School (HMS), and Co-Director of the Pulmonary Vascular Disease Center at the VA Boston Healthcare System, has been appointed Co-Director of the UMB’s new Institute for Health Computing (UM-IHC), Director of Scientific Operations for the UM-IHC at UMSOM, as well as Senior Associate Dean for Precision Medicine at the UMSOM, effective May 1, 2023.

• share
• favorite_border

A new technique designed to allow surgeons to identify and remove residual tumor tissue during breast-conserving surgery showed promising results in a multi-center trial led by investigators from the Mass General Cancer Center, a member of Mass General Brigham.

• share
• favorite_border

Cedars-Sinai recently appointed distinguished surgical oncologist Cristina Ferrone, MD, as chair of the Department of Surgery.

• share
• favorite_border

Novel research in sexual health by investigators at the Desai Sethi Urology Institute (DSUI) at the University of Miami Miller School of Medicine was presented at the 2023 American Urological Association (AUA), one of the world's most important urology meetings, and simultaneously published in, the Journal of Urology, one of the highest impact journals in the specialty.

• share
• favorite_border

A roundup of the latest medical discoveries and faculty news at Cedars-Sinai for April 2023.

• share
• favorite_border

Dogs with dementia suffer the same sleep disruptions that humans with dementia do.

• share
• favorite_border

One of the most highly-anticipated events at the ATS 2023 International Conference, which kicks off May 19, is the “Breaking News: Clinical Trial Results in Pulmonary Medicine.” Taking place on Monday, May 22, the series of presentations will focus on the latest regarding COPD and asthma treatment.

• share
• favorite_border

The Society for Clinical Trials (SCT) is pleased to announce that the prestigious David Sackett Trial of the Year Award will be presented to The Chronic Hypertension and Pregnancy (CHAP) Trial.

• share
• favorite_border

Susan G. Komen®, the world’s leading breast cancer organization, has appointed nine world-renowned medical and research experts to serve as advisors to the organization. These breast cancer experts will be part of a distinguished group, known as Komen Scholars, who help guide Komen’s research and scientific programs, with a focus on advancing discoveries to improve breast cancer outcomes for everyone.

• share
• favorite_border

A successful gene therapy trialed at Michigan State University in dogs with an inherited eye disease is ready to be developed for clinical use in human patients with a rare condition called retinitis pigmentosa.

• share
• favorite_border

UCLA Health investigators are leading a new, six-city trial of injectable buprenorphine for treatment of methamphetamine use disorder in adults who also use opioids.

• share
• favorite_border

UT Southwestern Medical Center will lead a national multicenter clinical trial to test a treatment strategy for pediatric cancer patients that has shown promising results in adults. The trial will examine the effects of combining several chemotherapy agents with an immunotherapy drug in children with solid tumors that have recurred or shown no significant response after initial treatment.

• share
• favorite_border

Researcher will discuss the study which involved a sleeping aid known as suvorexant that is already approved by the Food and Drug Administration (FDA) for insomnia, hints at the potential of sleep medications to slow or stop the progression of Alzheimer’s disease.

• share
• favorite_border

The underrepresentation of female research subjects has been documented from clinical trials down to sources for cell cultures. Now, researchers out of Marquette University in Milwaukee have found that in exercise research, this inequity correlates with the gender of the researchers conducting the study.

• share
• favorite_border

Vijay Goradia, a Houston-based businessman, philanthropist, and cancer survivor, has donated $10 million to The University of Texas MD Anderson Cancer Center to speed translational research and clinical trials.

• share
• favorite_border

UC Davis Health researchers have dosed the second participant in their clinical trial looking to identify a potential cure for HIV utilizing CART-cell therapy.

• share
• favorite_border

The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.

• share
• favorite_border

The National Institutes of Health trial to evaluate the mpox (previously known as monkeypox) vaccine JYNNEOS has now entered the next stage and is studying the immune responses to and the safety of the vaccine in adolescents. The George Washington University is one of 18 clinical trial sites across the United States that have launched this stage testing the JYNNEOS vaccine.

• share
• favorite_border

The immuno-oncology (IO) clinical trial landscape is shifting in new directions. While the number of total clinical trials is down, there are healthy signs of innovation.

• share
• favorite_border

Researchers from The University of Texas MD Anderson Cancer Center presented promising findings from multiple clinical trials today at the American Association for Cancer Research (AACR) Annual Meeting 2023. The studies, which describe results from a novel FGFR inhibitor and from new PARP/ATR inhibitor combinations, were featured in a plenary session highlighting novel biomarker-driven molecularly targeted therapy trials.

• share
• favorite_border

Research led by Roswell Park's Sarbajit Mukherjee, MD, MS, shows that a new chemotherapy combination — trifluridine/tipiracil (FTD/TPI) and oxaliplatin — is well tolerated and has activity among patients with esophageal cancer.

• share
• favorite_border

Indiana University Melvin and Bren Simon Comprehensive Cancer Center served as the lead site for a promising first-in-human clinical trial for patients with relapsed multiple myeloma. Patients treated with higher doses of the immunotherapy called REGN5459 resulted in a 90.5 percent overall response rate.

• share
• favorite_border

• share
• favorite_border

Researchers have made huge strides in ensuring that red blood cell substitutes – or artificial blood – are able to work safely and effectively when transfused into the bloodstream.

• share
• favorite_border

An international phase 3 clinical trial led by physicians at Washington University School of Medicine in St. Louis has shown that the investigational drug motixafortide — when combined with the standard therapy for mobilizing stem cells — significantly increases the number of stem cells that can be harvested, compared with treatment with the standard agent alone.

• share
• favorite_border

The CD70-targeting allogeneic chimeric antigen receptor (CAR) T cell therapy, ALLO-316, demonstrated encouraging response rates and disease control rates in patients with metastatic clear cell renal cell carcinoma (ccRCC), according to results of a Phase I trial led by researchers at The University of Texas MD Anderson Cancer Center and presented today at the American Association for Cancer Research (AACR) Annual Meeting 2023.

• share
• favorite_border

The first-in-class YAP/TEAD inhibitor VT3989 was well tolerated with durable antitumor responses in patients with advanced malignant mesothelioma and other tumors with NF2 mutations, according to results of a Phase I trial led by researchers at The University of Texas MD Anderson Cancer Center.

• share
• favorite_border

Results from a preclinical study from Penn Medicine, presented at the AACR Annual Meeting 2023, verified a new target for drug-resistant ovarian cancer and provided data to support a treatment approach that is already making its way into clinical trials.

• share
• favorite_border

A regimen of pre-surgical immunotherapy and chemotherapy followed by post-surgical immunotherapy significantly improved event-free survival (EFS) and pathologic complete response (pCR) rates compared to chemotherapy alone for patients with operable non-small cell lung cancer (NSCLC), according to Phase III trial results presented today by researchers from The University of Texas MD Anderson Cancer Center at the American Association for Cancer Research (AACR) Annual Meeting 2023.

• share
• favorite_border

Ochsner Health is one of 20 sites in the U.S. participating in the PROMISE II clinical trial, which was recently published in the New England Journal of Medicine.

• share
• favorite_border

UC San Francisco interventional cardiologists and interventional echocardiographers recently performed two novel minimally invasive cardiac procedures for the first time in the health system.

• share
• favorite_border

Investigators from Cedars-Sinai Cancer are collaborating on a streamlined clinical trial design in a study called Pragmatica-Lung.

• share
• favorite_border

A study published April 11 in the Journal of the American Medical Association (JAMA) evaluated two drugs that act on the renin-angiotensin system (RAS) as potential treatments for severe COVID-19. Severe acute respiratory syndrome coronavirus2 (SARS-CoV-2), the virus that causes COVID-19, enters pulmonary and myocardial cells through binding of its spike protein to the human angiotensin-converting enzyme 2 (ACE2). ACE2 is a vital enzyme that controls blood pressure and blood flow to multiple organs, including the lungs, heart and kidneys.

• share
• favorite_border

De acordo com uma pesquisa conduzida pela Aliança para Ensaios Clínicos em Oncologia e o Centro de Câncer da Mayo Clinic, pacientes com diversos tumores em um seio podem ser capazes de evitar uma mastectomia se os tumores puderem ser removidos enquanto uma quantidade suficiente de tecido mamário puder ser preservada.